Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...
Exclusive: A majority of Australians want the Federal Government to invest more in the Pharmaceutical Benefits Scheme (PBS) ...
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem ...
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partnering ...
Today, new-generation cancer drugs have significantly improved both effectiveness and safety, especially targeted therapies.
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
Often times, it takes the perspective of a youngster to realize something is amiss. For example, look at the beautiful ...
HENDERSON, Ky. (WFIE) - The Henderson Police Department is sharing some news on Stuart O’Nan, the lieutenant who has spent ...
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
Zacks Investment Research on MSN
Here's why Merck (MRK) is a strong growth stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) HoldersTAMPA, Fla., Dec. 15, 2025 /PRNewswire/ - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback